BLRX

$2.73+0.10 (+3.80%)

Market OpenAs of Mar 17, 6:59 PM UTC

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.73
Potential Downside
100%
Whystock Fair Value$0.00
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatm...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.81M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.46
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-21.24%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.90

Recent News

GuruFocus.com
Nov 29, 2025

BioLine Rx Ltd (BLRX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...

BioLine Rx Ltd (BLRX) reports reduced net loss and strategic developments in cancer treatment, bolstered by a strong cash position.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Insider Monkey
Jul 3, 2025

H.C. Wainwright Reaffirms Buy on BioLineRx Ltd. (BLRX) After ASCO 2025

BioLineRx Ltd. (NASDAQ:BLRX) is among the best growth stocks to invest in for the next 5 years. H.C. Wainwright reaffirmed its Buy rating on BioLineRx Ltd. (NASDAQ:BLRX) while maintaining a price target of $26.00. This confidence follows the company’s participation in ASCO 2025, where the management presented full data from the pilot phase of its […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
TipRanks
May 31, 2025

BioLineRx upgraded to Buy from Hold at JonesResearch

JonesResearch upgraded BioLineRx (BLRX) to Buy from Hold with a $12 price target The company announced new pilot phase data from the investigator-initiated Phase II combination trial of motixafortide plus PD-1 inhibitor cemiplimab plus chemo in first line pancreatic cancer where seven of 11 patients responded to therapy and 10 of 11 achieved disease control, the analyst tells investors in a research note. With these results, the firm believes BioLineRx will have additional opportunities to eithe

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Benzinga
May 30, 2025

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

BioLineRx Ltd’s (NASDAQ:BLRX) poster, which includes new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination trial, will be presented at the 2025 American Society of Clinical Oncology Annual Meeting. The CheMo4METPANC trial is evaluating motixafortide, cemiplimab, and standard-of-care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC). Updated results from

BEARISH
Negative press. News cycle fixated on risk factors or misses.
GuruFocus.com
May 28, 2025

BioLine Rx Ltd (BLRX) Q1 2025 Earnings Call Highlights: Transformational Moves and Financial ...

BioLine Rx Ltd (BLRX) reports a significant net income turnaround and strategic partnerships despite revenue challenges.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.